Cancer
Permanent URI for this collectionhttps://hdl.handle.net/20.500.12503/32539
Browse
Browsing Cancer by Author "Chaudhary, Pankaj"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item High expression of N-acetyl transferase 9 in cholangiocarcinoma and its possible role in tumor progression(2024-03-21) Hoteit, Tamara; Jones, Harlan; Chaudhary, PankajCholangiocarcinoma, CCA, is an aggressive type of liver cancer due to the scarce number of biomarkers and its resistance to anticancer drugs, leading to difficulty in its early detection. Its 5-year survival rate ranges from 2% to 24%, depending on severity and metastasis. Currently, surgery is the most effective treatment option, but only under certain criteria, such as the cancer being caught early and having not metastasized. CCA incidence is the highest in Asian countries because of the presence of a carcinogenic liver fluke. N-acetyl transferase, NAT, is an enzyme with many functions, including regulating protein stability, membrane targeting, gene silencing, and drug resistance. Different subsets of NATs are also known to be biomarkers for different types of cancer, such as colorectal, prostate, and breast cancers. According to The Cancer Genome Atlas database, NAT9, a subset of the NAT family, is overexpressed in patients with CCA; however, no studies have demonstrated its role in CCA, indicating the need for more research. In this study, we aim to assess the expression of NAT9 in CCA using cell lines and patient tissue samples through RT-qPCR, western blotting, and immunohistochemistry. This data will help us shed light on NAT9’s role in the tumorigenesis of CCA and could be a promising biomarker and therapeutic target for CCA.Item Understanding the role of Annexin A2 expression in the incidence of Hepatocellular Carcinoma.(2024-03-21) Fiadjoe, Hope; Chaudhary, PankajPurpose: Hepatocellular carcinoma (HCC) is a rapidly growing cancer with high mortality rates worldwide, necessitating improved diagnostic and therapeutic strategies. Annexin A2 (AnxA2), a calcium-dependent phospholipid-binding protein and a member of the annexin protein family, holds promise as a diagnostic, prognostic, and therapeutic target in several cancers. This study evaluates the clinical significance of AnxA2 in HCC progression. Methods: The Cancer Genome Atlas (TCGA) data was mined to assess AnxA2 mRNA expression in HCC and its correlation with tumor stage, grade, overall survival, and progression-free survival. Additionally, immunoblot analysis was conducted on tumor tissue samples to determine the AnxA2 expression in HCC patients. Results: Analysis of TCGA data revealed a significant upregulation of AnxA2 mRNA expression in HCC compared to normal liver tissues, correlating with higher pathological grades and stages and poor overall and progression-free survival. The immunoblot analysis further confirmed that the expression of AnxA2 was high in tumor tissues of HCC patients compared to matched adjacent non-tumorigenic liver tissues. Conclusion: These findings underscore the potential of AnxA2 as a biomarker for cancer aggressiveness and prognosis, highlighting its role as a promising therapeutic target.